•
December 9, 2022

SABCS Reactions - MonarchE

•
December 9, 2022

SABCS Reactions - MonarchE

Author
Back to Blog

Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: results from a pre-planned monarchE overall survival interim analysis, including 4-year efficacy outcomes

‍

Abstract #GS1-09: Prof. Stephen Johnston presented interim OS data from the P3 monarchE trial, assessing abemaciclib plus endocrine therapy (ET) in 5,637 patients with HR+, HER2-, node-positive, high-risk early breast cancer.

‍

‍Results:

  • Abemaciclib demonstrated sustained benefit even after discontinuation – invasive disease-free survival (IDFS) 4-year rates were better than 2- and 3-year
  • At 4 years, rates of IDFS in the abemaciclib + ET arm were 85.8% vs 79.4% in the ET only arm
  • Rates of distant relapse-free survival (DRFS)were 88.4% in the abema + ET arm vs 82.8% in the ET alone arm
  • OS remains immature; but fewer deaths occurred in the abema + ET arm vs the ET alone arm (5.6% vs 6.1%)
  • No new safety signals observed

    • ‍

    sabcs

    ‍

    While many thought leaders find the IDFS and DRFS benefit and reduced recurrence risk encouraging . . .

    ‍

    Hope-MonarchE
    Gustavo
    Matteo

    . . . they await mature OS data and claim that practice is unlikely to change until demonstrable OS benefit is shown.

    ‍

    Sid Yadav
    Bijoy

    ‍

    Saroj

    ‍

    Managing abemaciclib side effects will be increasingly important given lasting efficacy.

    ‍

    Benedetta
    Nicole
    Eleonora

    ‍

    Summary:

    ‍Though abemaciclib plus endocrine therapy (ET) provides sustained benefit in HR+, HER2-, node-positive, high-risk early breast cancer, the combination is unlikely to be practice changing until it demonstrates improved OS.

    ‍

    Synthesis by Opus Strategy, LLC

    Opus

    ‍

    ‍

    Download attached file
    Not rated
    Allison Betof Warner, MD, PhD (she/her) 4
    3743
    Manhattan, NY
    November 10, 2022

    79% had reduction in disease. ORR 31%. Many responses deepen over time.

    Not rated
    Allison Betof Warner, MD, PhD (she/her) 3
    3743
    Manhattan, NY
    November 10, 2022

    Median DOR not yet reached. Median OS 13.9 mo. 12 mo OS was 54%. As typical with immunotherapy, we see a nice tail on the curve. #TIL#SITC22

    Positive
    Alex Shoushtari, MD
    2253
    New York, USA
    November 10, 2022

    Important work on efficacy of TIL therapy lifileucel in PD-1 resistant #melanoma being presented at #SITC22. Pretty good durability for this heavy lift of a treatment.

    Not rated
    Allison Betof Warner, MD, PhD (she/her) 2
    3743
    Manhattan, NY
    November 10, 2022

    Toxicity profile was in line with prior TIL/Lifileucel data. No surprises here. Median # doses of IL-2 was 6.

    Positive
    Hussein Tawbi, MD, PhD
    1685
    Houston, TX
    November 10, 2022

    Absolutely agree!… this should be available to our melanoma patients ASAP!… and paves the way for smarter cellular therapies to be designed, studied, and eventually widely disseminated

    Positive
    Allison Betof Warner, MD, PhD (she/her) 1
    3744
    Manhattan, NY
    November 10, 2022

    Where does this leave us with #TIL therapy for #melanoma? IMO, this response rate/durability justifies accelerated approval. Pts with PD-1 refractory melanoma need options. It’s FAR from a perfect tx but provides meaningful clinical benefit. What say you melanoma Twitterverse?

    Not Rated
    Sumanta K. Pal, MD, FASCO
    15083 Followers
    Los Angeles, CA
    November 8, 2022

    Just before I start AM clinic at @cityofhopeoc, excited to share results from #COBALT_RCC, a P1 trial of @CRISPRTX#CTX130 in #kidneycancer in the @sitcancer#PressProgram. Will present more on Thurs 5:37p at #SITC22! Thx @neerajaiims@DrBenTran@HaanenJohn#SamerSrour& co-Is! t.co/aDnhG9n92A

    not rated
    Shilpa Gupta
    5095 Followers
    Cleveland, OH
    November 8, 2022

    @montypal@cityofhopeoc@CRISPRTX@sitcancer@neerajaiims@DrBenTran@HaanenJohn@DrChoueiri@TiansterZhang@tompowles1@brian_rini@AlbigesL@Uromigos@ERPlimackMD@drenriquegrande@PGrivasMDPhD Congrats Monty! Looking forward to hearing about this exciting first-in the field study!

    Not Rated
    Tian Zhang, MD, MHS
    6463 Followers
    Dallas, TX
    November 8, 2022

    CAR-Ts are coming for #kidneycancer!! Congratulations @montypal and team; can’t wait to see results at #SITC22! t.co/9MrlF2yzBe

    Not Rated
    Moshe Ornstein MD
    1930 Followers
    Cleveland, OH
    November 8, 2022

    Congrats @montypal and team! Great to see CAR T therapy coming to #RCCt.co/ypRHBC89Pt

    Not Rated
    Shuchi Gulati MD
    12476 Followers
    Seattle, WA
    November 8, 2022

    Another huge step from none other than @montypal!! CAR-Ts in #kidneycancer!Congratulations to the entire team!Looking forward to seeing the results at #SITC22! t.co/HvKeVBPyV7

    Not Rated
    Petros Grivas
    12476 Followers
    Seattle, WA
    November 8, 2022

    @montypal you never stop to amaze me! You are brilliant & awesome! Looking forward to hearing more about this trial @sitcancer@OncoAlert@CityofHope_GU@COHMDCareers@neerajaiims@KidneyCancer@KidneyCancerDoc@NazliDizman@ZeynepZengin@LuisMezaco@crisbergerot@PauloBergerott.co/RNzOwxixQm

    Subscribe to our newsletter

    Sign up for our newsletter to get the latest news, updates and high-impact data delivered directly to your inbox.
    Thank you! Your submission has been received!
    Oops! Something went wrong while submitting the form.
    Other Posts
    Blog Posts
    •
    August 9, 2023

    From Passion to Profession: Meet LARVOL’s VP Sales, Linh Nguyen

    In this edition of our ongoing series "In The Spotlight", we're excited to chat with Linh Nguyen, the VP Sales at LARVOL. With a passion for healthcare and a commitment to making a difference in the oncology field, Linh has been a vital part of our team for over six years. Let’s get to know Linh better through her own words, exploring her journey, motivations, and the personal interests that round out her life.

    Read more
    Blog Posts
    •
    August 9, 2023

    Our Shift to the Metaverse: A Conversation with CEO Bruno Larvol

    In 2020, as most of the business world wrestled with the transition to remote work, my company chose an alternate approach. As Founder and CEO, I began pushing for a very different but equally culture-shifting change. I moved our corporate headquarters to the metaverse, and we’re never looking back.

    Read more
    Blog Posts
    •
    August 9, 2023

    The Latest in ADCs: Precision Tools in Cancer Treatment

    The battle against cancer is shifting, with Antibody-Drug Conjugates (ADCs) leading a revolution in precision therapy. These biological innovators are changing the game for many patients, offering a glimmer of hope in an often daunting prognosis. Here’s a closer look at the promising world of ADCs and how they're transforming cancer care.

    Read more
    Blog Posts
    •
    August 9, 2023

    LARVOL's CONF Case Study: An In-depth Q&A with Angela Kaya, Director of Publications & Scientific Communications at PMV Pharma

    Navigating the busy world of pharmaceutical conferences can be a daunting task, filled with endless sessions, abstracts, and updates to keep track of. This is where LARVOL CONF comes into play – offering a simple, yet powerful way to organize and manage conference information effectively.

    Read more
    Larvo logo footer

    Solutions

    Insights

    Company

    LARVOL & SEMPER TIGRIS are registered trademarks in the European Community
    Copyright © LARVOL 2023
    Privacy PolicyKOL Privacy PolicyAcceptable Use Policy
    Waves